<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327482</url>
  </required_header>
  <id_info>
    <org_study_id>38681-D</org_study_id>
    <nct_id>NCT01327482</nct_id>
  </id_info>
  <brief_title>Levels of Raltegravir in the Female Genital Tissue</brief_title>
  <official_title>Modeling Intracellular and Extracellular Raltegravir (RAL) Pharmacokinetics in the Female Genital Tract and Blood After a Twice Daily 400mg Dose Over the Course of a Menstrual Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an investigation of the pharmacokinetics of raltegravir in the tissue of the
      female genital tract to determine if twice-daily dosing of 400mg achieves adequate drug
      levels to prevent viral integration of HIV-1. The study will also assess whether drug levels
      change in the tissue across the different phases of the menstrual cycle.

        -  Hypothesis #1: Twice daily dosing with raltegravir 400mg will result in intracellular
           concentrations that should be sufficient to suppress HIV-1 replication throughout the
           menstrual cycle.

        -  Hypothesis #2: Intracellular genital raltegravir peaks will be lower and troughs higher
           compared to extracellular concentrations in the plasma and PMBCs (peripheral blood
           mononuclear cells).

        -  Hypothesis #3: Intracellular raltegravir concentrations will be slightly lower during
           the luteal phase of the menstrual cycle due to cellular pumps such as p-glycoprotein,
           which are present in higher numbers during periods of high progesterone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 is shed in genital secretions which increase the risk of transmission between sexual
      partners and from mother to infant. Antiretroviral medication taken prior to exposure to
      HIV-1 can prevent viral transmission from a mother to her infant. Raltegravir (RAL), by
      blocking integration of viral cDNA into the host's genome, makes an excellent candidate for
      preventing HIV-1 infection. RAL is licensed for treatment with twice-daily dosing based on
      plasma trough concentrations; however, intracellular concentrations of RAL which are relevant
      to blocking infection of cells have not been previously studied. P-glycoprotein pumps, which
      are involved in regulating drug absorption and metabolism, can influence intracellular drug
      concentrations. P-glycoprotein concentrations appear to vary with menstrual cycle suggesting
      it may affect intracellular drug concentration of RAL in women.

      Women will be enrolled in the study and followed during the course of a menstrual cycle while
      taking a dose of 400mg PO twice daily. An initial screening visit will be performed prior to
      enrollment and participation in the study. Review of medical history as well as blood and
      urine collection will occur during the screening visit. Once enrolled, participants will have
      blood and genital tract samples collected once a week for four weeks to assess intracellular
      concentrations of RAL in the blood and genital tract tissue.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue Raltegravir Concentrations</measure>
    <time_frame>7, 14, 21 days</time_frame>
    <description>Mean trough concentration from all three days. Tissue concentrations are measured from cervical biopsy homogenate using a mass-spectroscopy-based method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Raltegravir Concentrations</measure>
    <time_frame>7, 14, 21 days</time_frame>
    <description>Mean trough concentration from all 3 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>All</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were part of the intervention arm, as this was a pharmacokinetic study. All women took Raltegravir 400mg orally, twice daily for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)</description>
    <arm_group_label>All</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Volunteers must be:

          -  Over 18 years of age.

          -  Willing to abstain from sexual intercourse during course of study.

          -  Able to commit to follow-up visit schedule.

          -  Willing to abstain from use of vaginal medications or creams 48 hours prior to
             follow-up visits.

          -  Willing and able to provide informed consent.

        Exclusion Criteria

        Volunteers will not be eligible for the study if they:

          -  Are over 50 years of age.

          -  Are pregnant, attempting to become pregnant, or breast-feeding.

          -  Have irregular menstrual bleeding.

          -  Are using a hormonal form of birth control.

          -  Have abnormal liver/kidney function test results at screening visit.

          -  Have HIV-positive test result at screening visit.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Mitchell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Frenkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington, Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <results_first_submitted>December 10, 2014</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2014</results_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Caroline Mitchell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir</title>
          <description>Healthy volunteers who had regular menses and were not on hormonal contraception</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">The 10th participant completed 2/3 visits</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir</title>
          <description>Healthy volunteers who had regular menses and were not on hormonal contraception</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tissue Raltegravir Concentrations</title>
        <description>Mean trough concentration from all three days. Tissue concentrations are measured from cervical biopsy homogenate using a mass-spectroscopy-based method.</description>
        <time_frame>7, 14, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Healthy volunteers who had regular menses and were not on hormonal contraception</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue Raltegravir Concentrations</title>
          <description>Mean trough concentration from all three days. Tissue concentrations are measured from cervical biopsy homogenate using a mass-spectroscopy-based method.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" spread="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Raltegravir Concentrations</title>
        <description>Mean trough concentration from all 3 days</description>
        <time_frame>7, 14, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Healthy volunteers who had regular menses and were not on hormonal contraception</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Raltegravir Concentrations</title>
          <description>Mean trough concentration from all 3 days</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir</title>
          <description>Healthy volunteers who had regular menses and were not on hormonal contraception</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Caroline Mitchell</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-2182</phone>
      <email>caroline.mitchell@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

